ECE2016 Guided Posters Diabetes (2) (10 abstracts)
Real-world comparative effectiveness of liraglutide, exenatide once weekly and lisixenatide in patients with type 2 diabetes mellitus
Amparo Marco Martínez 1 , Ana Martínez García 1 , Sandra Herranz Antolín 2 , Gemma López Gallardo 3 , Pedro José Pinés Corrales 4 , Rosa Quilez Toboso 5 , Miguel Aguirre Sanchez-Covisa 6 & Jose Joaquín Alfaro 7
1Servicio de Endocrinología y Nutrición. Complejo Hospitalario de Toledo, Toledo, Spain; 2Servicio de Endocrinología y Nutrición. Hospital Universitario de Guadalajara, Guadalajara, Spain; 3Servicio de Endocrinología y Nutrición. Hospital Santa Bárbara, Puertollano. Ciudad Real, Spain; 4Servicio de Endocrinología y Nutrición. Hospital General de Almansa, Almansa. Albacete, Spain; 5Servicio de Endocrinología y Nutrición. Hospital General de Villarrobledo, Villarrobledo. Albacete, Spain; 6Servicio de Endocrinología y Nutrición. Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; 7Servisio de Endocrinología. Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
The improvement of glycemic control and body weight reduction by GLP-1 receptor agonist (GLP1RA) has been demostred in randomized clinical trials, but comparative studies of the efficacy of different GLP1RA in real world and clinical practice setting are limited.
Objectives: To compare the efficacy of liraglutide (LIRA), exenatide once weekly (EQW), and lisixenatide (LIXI) treatment in a real-world and clinical practice setting.
Methods: Prospective, longitudinal, multicenter, and not randomized study that compares HbA1c and body weight reduction in 135 patients with type 2 DM treated for six months with LIRA, EQW or LIXI. Data for continous variables are presented as mean (SD) and for categorical variables as percentajes.
Results: 52.6% men, age 53.9 (9.7) years, 6.7% <1 years of evolution, 23.7% 1–5, 25.8% 5–10 and 41.5% >10, mean baseline weight 102.5 (18.6) kg, BMI 37.7 (5.9) kg/m2, HbA1c 8.4% (1.4). 83 (61.4%) patients were treated with LIRA, 30 (22.2%) with EQW and 22 (16%) with LIXI. There were no differences between the three groups regarding the baseline parametres. After 6 months we observed change of Hba1c −1.09% (1.18) P<0.001 (−1.2%(1.4) LIRA, −1.1% (1.2) EQW, P<0.001 for both and −0.8%(1.8) ns LIXI). Weight −3.6 kg (4.1) (−3.9 kg (5.5) LIRA, −3.6 kg (4.1) EQW P<0.001 for both, −2.8 kg (3.6) LIXI ns). Composite end points was analized, 47.4% achieved HbA1c<7% (59.2% LIRA, 46.4% EQW, 35.3% LIXI), 45.2% weight reduction >3% (52.7% LIRA, 55.6% EQW, 41.2% LIXI), 25.9% both parameters (31.1% LIRA, 37.5% EQW 11.8% LIXI). No differences was observed between groups.6 (4.4%) patients were lost from follow up (four LIRA, two EQW) and 26 (19.3%) discontinued the treatment (14 (16.8%) LIRA, 1 (3%) EQW and 11 (50%) LIXI).
Conclusions: In a real-world setting, HbA1c improved similarly in patients initiating EQW or LIRA, and minor efficacy was observed in LIXI group. Weight reducction was similar in all groups of treatment. The biggest proportion of treatment discontinuation was observerd among members of the LIXI group.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more